-->

Ad Unit (Iklan) BIG

Home  ›  Uncategorized

Business Wire India - Multimedia: Digest for December 23, 2023

Business Wire India - Multimedia

Multimedia By Business Wire India
Business Wire India

Sony Sports Network, the premier destination for football in India, has joined hands with Bollywood's Gen Z superstar and youth icon - Kartik Aaryan, who is known to be a die-hard football fan, to become their Brand Ambassador for football. During his partnership with Sony Sports Network, Kartik will be seen promoting LIVE football action on Sony Sports Network around the year with 900+ matches from marquee football tournaments and leagues which include UEFA EURO 2024, UEFA Champions League, UEFA Europa League, UEFA Conference League, UEFA Nations League, Bundesliga, Emirates FA Cup, Durand Cup and Roshn Saudi League amongst others.
 
Kartik Aaryan who has enthralled audiences with stellar performances on the silver screen is also known for his enthusiasm and fandom for the game of football. His love for the game began at an early age and he is a dedicated Real Madrid fan, the most successful club in the history of the UEFA Champions League.
 
Comments:

Rajesh Kaul, Chief Revenue Officer - Distribution & International Business and Head - Sports Business, Sony Pictures Networks India:
"It gives us immense pleasure to announce Kartik Aaryan as the Brand Ambassador of football on Sony Sports Network. Kartik is a true star on the silver screen and a passionate voice for football which resonates very well with audiences. We aim to connect with the Indian youth and create a deeper engagement with our ever-growing football viewers through Kartik Aaryan for our diverse portfolio of football offerings that includes the live telecast of over 900 football matches and positions Sony Sports Network as the premier destination for football."

Kartik Aaryan, Bollywood Actor & Brand Ambassador for Football on Sony Sports Network:
"I have been an ardent football fan since I was a child and I feel privileged to partner with Sony Sports Network for promoting a sport that is so close to my heart. Sony Sports Network will be home to some of the best footballing action for the year ahead from UEFA EURO 2024 to UEFA Champions League, Bundesliga and more. I am excited about the football broadcast calendar which will showcase the best players and teams from across the world. I'm really looking forward to watching my favourite footballers play on the ground and meet them. I can't wait to share the adrenaline rush in the stadium with other football fanatics and live the madness!"
 
Armed with the vision of reaching out to a wider stratum of Indian audiences and bringing them closer to the game, Sony Sports Network has launched the first film from the 'Your Home of Football' campaign which will be followed by four additional films in the coming weeks. The films featuring Kartik Aaryan will showcase the broadcaster's repertoire of football offerings along with the actor's deep love for the game.
 
Film: Every Football Fan is Different
The film is an ode to the fans of the various football properties on Sony Sports Network, highlighting the broadcaster's depth of football content. In the film, Kartik is seen essaying the role of the different types of fans for different leagues and tournaments while donning their team jerseys. All with one common link between all the offerings: establishing that there is only one destination for all these football fans and that is Sony Sports Network.

Link to film: https://www.youtube.com/watch?v=eMNzmCYJnSQ
 
Fans can watch the LIVE coverage of the UEFA Champions League, Bundesliga, Emirates FA Cup, Bundesliga, Roshn Saudi League, UEFA EURO 2024, Europa League, UEFA Conference League, UEFA Nations League, Durand Cup and more on Sony Sports Network.
 
For the latest updates from the world of sport, follow the Sony Sports Network on Instagram, Twitter, Facebook and subscribe to our YouTube channel.
Business Wire India

India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc (NYSE: MDT), announced the launch of the Symplicity™ Spyral renal denervation system (RDN) for treating high blood pressure. RDN is a minimally invasive therapy that targets nerves near the kidneys that can become overactive and cause high blood pressure. Medtronic recently announced the US Food and Drug Administration's (FDA) approval of the system which is a culmination of ten years of clinical research and development, and the system has approval of the Indian regulatory authorities too.
 
In India, nearly 1 in 4 adults have hypertension.[i] Hypertension is the single largest contributor to cardiovascular death; it dramatically increases risk of heart attack, stroke, heart failure, and kidney failure. Unfortunately, hypertension often goes undiagnosed as it frequently exhibits no symptoms. Raising awareness about hypertension is crucial since it is a detectable, preventable and treatable condition.
 
The Symplicity SpyralTM blood pressure procedure has demonstrated clinical efficacy in reducing high blood pressure[ii],[iii],[iv] which can lower serious health risks[v]. It is a minimally invasive procedure that targets nerves near the kidneys that can become overactive and cause elevated blood pressure. After sedation, the doctor makes a small incision and inserts a very thin tube (catheter) into the artery leading to the kidney. The doctor then uses the catheter to calm the excessive activity of the nerves connected to the kidney. The tube is removed, leaving no implant behind.
 
Michael Blackwell, Vice President and Managing Director, Medtronic India said, "With the Symplicity blood pressure procedure, we aim to empower healthcare professionals and offer a comprehensive approach to managing uncontrolled hypertension that supports our patient-centered approach to care. The recently announced US FDA approval for the RDN system and an update earlier this year of the European Hypertension Society (ESH) guidelines, highlight the role of RDN as part of the hypertension care pathway. We are excited to offer this therapy to all eligible patients in India. As leaders in cardiovascular therapies, Medtronic remains committed to providing innovative solutions that improve patients' lives."
 
The Medtronic RDN program is backed by experience in more than 25,000 patients globally. It has also been studied in more than 4,000 patients in the presence and absence of medication, and in patients with high baseline cardiovascular risk, or with comorbidities. It has demonstrated significant and sustained reductions in blood pressure among patients with uncontrolled hypertension. Further, the procedure has been proven to be safe, with very low rates of adverse events.[vi]
 
Know the facts & talk to your doctor

Blood pressure is the force that circulating blood exerts against the walls of the arteries – and hypertension is when blood pressure is abnormally high. Hypertension is often called the "silent killer" because most people don't know they have it. Although there may not be any warning signs or symptoms shown, some people report early morning headaches, nosebleeds, irregular heart rhythms and buzzing in the ears. Hypertension can significantly increase the risks of heart, brain, kidney, and other diseases and is a major cause of premature death. vi If you or someone you know is experiencing high or difficult to control blood pressure, consult with your doctor to learn more about the Symplicity™ procedure.
 
[I] Geldsetzer P, Manne‐Goehler J, Theilmann M, et al. Diabetes and hypertension in India: a nationally representative study of 1.3 million adults. JAMA Intern Med. 2018;178(3):363‐372 ----
renissl J, Manne‐Goehler J, Jaacks LM, et al. Hypertension screening, awareness, treatment, and control in India: a nationally representative cross‐sectional study among individuals aged 15 to 49 years. PLoS Med. 2019;16(5):e1002801
 
[ii] Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet. 2018 Jun 9;391(10137):2346-2355.
.
[iii] Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomized, sham-controlled trial. The Lancet 2020; Published online March 29, 2020. DOI: 10.1016/S0140-6736(20)30554-7.
 
[iv] Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. The Lancet. 2017;390:2160–2170.

[iv] Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387:957-67.
 
[v] Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387:957-67.
 
[vi] Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomized, sham-controlled trial. The Lancet 2020; Published online March 29, 2020. DOI: 10.1016/S0140-6736(20)30554-7.
You received this email because you set up a subscription at Feedrabbit. This email was sent to you at epaperindia10@gmail.com. Unsubscribe or change your subscription.

Related Posts

There is no other posts in this category.
Subscribe Our Newsletter